Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Expenses:
Research and development	$ 2,608,357	$ 2,812,760
General and administrative	2,063,897	2,150,816
Total Operating Expenses	4,672,254	4,963,576
Total Operating Loss	(4,672,254)	(4,963,576)
Other Income/(Expense):
EIDL grant		3,000
Research and development tax credit	31,315	27,694
Investment and interest income	4	3,415
Gain from forgiveness of PPP Loan and interest	63,094
Interest expense	(961,702)	(1,748,120)
Total Other Expense, Net	(867,289)	(1,714,011)
Net Loss	$ (5,539,543)	$ (6,677,587)
Basic and Diluted Loss Per Common Share	$ (0.01)	$ (0.02)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	408,223,004	393,252,321